The University of Chicago Header Logo

Connection

Michael Davidson to Double-Blind Method

Back to Details
This is a "connection" page, showing publications Michael Davidson has written about Double-Blind Method.
Michael Davidson
Connection Strength
4.295
Double-Blind Method
  1. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
    View in: PubMed
    Score: 0.174
  2. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022 08; 28(8):1672-1678.
    View in: PubMed
    Score: 0.140
  3. The effects of JNJ-39393406 a positive allosteric nicotine modulator on mood and cognition in patients with unipolar depression: A double-blind, add-on, placebo-controlled trial. Eur Neuropsychopharmacol. 2021 10; 51:33-42.
    View in: PubMed
    Score: 0.129
  4. Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2021 01; 32(1):211-222.
    View in: PubMed
    Score: 0.125
  5. The brief negative symptom scale (BNSS): Sensitivity to treatment effects. Schizophr Res. 2018 07; 197:269-273.
    View in: PubMed
    Score: 0.102
  6. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017 12 01; 174(12):1195-1202.
    View in: PubMed
    Score: 0.099
  7. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. Lipids Health Dis. 2015 Sep 02; 14:98.
    View in: PubMed
    Score: 0.087
  8. Assessment of the effect of esterified propoxylated glycerol (EPG) on the status of fat-soluble vitamins and select water-soluble nutrients following dietary administration to humans for 8 weeks. Regul Toxicol Pharmacol. 2014 Dec; 70 Suppl 2:S143-57.
    View in: PubMed
    Score: 0.083
  9. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther. 2014 Aug 01; 36(8):1211-22.
    View in: PubMed
    Score: 0.080
  10. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014 Jun; 34(6):1298-306.
    View in: PubMed
    Score: 0.079
  11. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013 Dec 10; 62(23):2178-84.
    View in: PubMed
    Score: 0.076
  12. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013 Sep; 35(9):1400-11.e1-3.
    View in: PubMed
    Score: 0.076
  13. Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. Atherosclerosis. 2013 Oct; 230(2):322-9.
    View in: PubMed
    Score: 0.075
  14. The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clin Ther. 2013 Aug; 35(8):1247-52.
    View in: PubMed
    Score: 0.075
  15. Bl-1020, a new ?-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J Clin Psychiatry. 2012 Sep; 73(9):e1168-74.
    View in: PubMed
    Score: 0.071
  16. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
    View in: PubMed
    Score: 0.070
  17. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am J Cardiovasc Drugs. 2010; 10(5):305-14.
    View in: PubMed
    Score: 0.059
  18. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009 Dec; 31(12):2824-38.
    View in: PubMed
    Score: 0.058
  19. Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J Cardiol. 2009 Oct 01; 104(7):936-42.
    View in: PubMed
    Score: 0.058
  20. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007 Jul; 29(7):1354-67.
    View in: PubMed
    Score: 0.049
  21. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006 Nov 07; 48(9):1774-81.
    View in: PubMed
    Score: 0.047
  22. Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry. 2006 Jul; 189:31-5.
    View in: PubMed
    Score: 0.046
  23. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 2006 Jun; 29(6):268-73.
    View in: PubMed
    Score: 0.046
  24. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005 Oct; 162(10):1888-95.
    View in: PubMed
    Score: 0.044
  25. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr. 2005 Jun; 24(3):189-99.
    View in: PubMed
    Score: 0.043
  26. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2005 Jun; 27(6):715-27.
    View in: PubMed
    Score: 0.043
  27. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
    View in: PubMed
    Score: 0.042
  28. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025 05 17; 405(10491):1757-1768.
    View in: PubMed
    Score: 0.042
  29. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
    View in: PubMed
    Score: 0.040
  30. Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition. Eur Neuropsychopharmacol. 2024 Oct; 87:18-23.
    View in: PubMed
    Score: 0.040
  31. Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial. Cardiovasc Res. 2024 05 29; 120(7):678-680.
    View in: PubMed
    Score: 0.040
  32. Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
    View in: PubMed
    Score: 0.040
  33. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. Clin Ther. 2003 Nov; 25(11):2738-53.
    View in: PubMed
    Score: 0.038
  34. Lipid responses in mildly hypertriglyceridemic men and women to consumption of docosahexaenoic acid-enriched eggs. Int J Vitam Nutr Res. 2003 Oct; 73(5):357-68.
    View in: PubMed
    Score: 0.038
  35. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis. 2003 Jul; 169(1):113-20.
    View in: PubMed
    Score: 0.037
  36. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
    View in: PubMed
    Score: 0.037
  37. A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2023 08; 73:65-74.
    View in: PubMed
    Score: 0.037
  38. Long-term effects of Roluperidone on negative symptoms of schizophrenia. Schizophr Res. 2023 05; 255:9-13.
    View in: PubMed
    Score: 0.037
  39. Food products containing free tall oil-based phytosterols and oat beta-glucan lower serum total and LDL cholesterol in hypercholesterolemic adults. J Nutr. 2003 Mar; 133(3):808-13.
    View in: PubMed
    Score: 0.036
  40. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002 Dec 18; 40(12):2125-34.
    View in: PubMed
    Score: 0.036
  41. Relationship between premorbid functioning and symptom severity as assessed at first episode of psychosis. Am J Psychiatry. 2002 Dec; 159(12):2021-6.
    View in: PubMed
    Score: 0.036
  42. Add-On Pramipexole for the Treatment of Schizophrenia and Schizoaffective Disorder: A Randomized Controlled Trial. J Clin Psychiatry. 2022 08 01; 83(5).
    View in: PubMed
    Score: 0.035
  43. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002 Feb 01; 89(3):268-75.
    View in: PubMed
    Score: 0.034
  44. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001 Oct; 76(10):971-82.
    View in: PubMed
    Score: 0.033
  45. Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women. J Am Coll Nutr. 2001 Aug; 20(4):307-19.
    View in: PubMed
    Score: 0.033
  46. Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two Randomized Controlled Trials. Schizophr Bull. 2021 07 08; 47(4):1077-1087.
    View in: PubMed
    Score: 0.033
  47. Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophr Res. 2001 May 30; 50(1-2):89-93.
    View in: PubMed
    Score: 0.032
  48. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 05 29; 397(10289):2060-2069.
    View in: PubMed
    Score: 0.032
  49. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry. 2001 May; 62(5):343-6.
    View in: PubMed
    Score: 0.032
  50. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020 12 08; 324(22):2268-2280.
    View in: PubMed
    Score: 0.031
  51. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med. 2000 Nov 27; 160(21):3315-25.
    View in: PubMed
    Score: 0.031
  52. Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. Clin Invest Med. 2000 Oct; 23(5):300-10.
    View in: PubMed
    Score: 0.031
  53. Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2000 Oct; 10(5):253-62.
    View in: PubMed
    Score: 0.031
  54. Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial. Schizophr Bull. 2020 07 08; 46(4):964-970.
    View in: PubMed
    Score: 0.030
  55. Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort. Eur Neuropsychopharmacol. 2020 03; 32:131-135.
    View in: PubMed
    Score: 0.030
  56. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. Am J Public Health. 1999 Nov; 89(11):1701-7.
    View in: PubMed
    Score: 0.029
  57. Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial. JAMA Psychiatry. 2019 10 01; 76(10):1009-1017.
    View in: PubMed
    Score: 0.029
  58. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999 Sep 13; 159(16):1893-900.
    View in: PubMed
    Score: 0.029
  59. Effects of dietary inulin on serum lipids. J Nutr. 1999 07; 129(7 Suppl):1474S-7S.
    View in: PubMed
    Score: 0.028
  60. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999 Jan 20; 281(3):235-42.
    View in: PubMed
    Score: 0.027
  61. The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial. Schizophr Res. 2019 04; 206:325-332.
    View in: PubMed
    Score: 0.027
  62. Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. Arch Fam Med. 1998 Nov-Dec; 7(6):569-74.
    View in: PubMed
    Score: 0.027
  63. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc. 2018 09 18; 7(18):e009221.
    View in: PubMed
    Score: 0.027
  64. Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. J Clin Psychiatry. 2018 May/Jun; 79(3).
    View in: PubMed
    Score: 0.026
  65. Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia. Am J Clin Nutr. 1998 Mar; 67(3):367-76.
    View in: PubMed
    Score: 0.026
  66. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. J Clin Lipidol. 2018 Mar - Apr; 12(2):321-330.
    View in: PubMed
    Score: 0.025
  67. Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Am J Cardiol. 1997 Sep 15; 80(6):797-8.
    View in: PubMed
    Score: 0.025
  68. Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry. 1997 Jul 15; 42(2):138-43.
    View in: PubMed
    Score: 0.025
  69. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med. 1997 Jun 09; 157(11):1186-92.
    View in: PubMed
    Score: 0.025
  70. Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. J Am Coll Nutr. 1997 Jun; 16(3):236-43.
    View in: PubMed
    Score: 0.024
  71. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol. 1997 Jun 01; 79(11):1475-81.
    View in: PubMed
    Score: 0.024
  72. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 1997 Jan 01; 79(1):38-42.
    View in: PubMed
    Score: 0.024
  73. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13; 134(24):1931-1943.
    View in: PubMed
    Score: 0.023
  74. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. J Clin Lipidol. 2016 Nov - Dec; 10(6):1442-1451.e4.
    View in: PubMed
    Score: 0.023
  75. A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study. Am J Clin Nutr. 1996 Jan; 63(1):96-102.
    View in: PubMed
    Score: 0.022
  76. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. J Clin Lipidol. 2015 Jan-Feb; 9(1):65-71.
    View in: PubMed
    Score: 0.020
  77. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24; 62(13):1154-62.
    View in: PubMed
    Score: 0.019
  78. Effect of m-chlorophenylpiperazine on plasma homovanillic acid concentrations in healthy subjects. Biol Psychiatry. 1992 Dec 01; 32(11):1055-61.
    View in: PubMed
    Score: 0.018
  79. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012 Jun; 73(6):e728-34.
    View in: PubMed
    Score: 0.017
  80. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. Am J Cardiovasc Drugs. 2012 Apr 01; 12(2):117-25.
    View in: PubMed
    Score: 0.017
  81. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int J Cardiol. 2013 Jul 15; 167(1):225-31.
    View in: PubMed
    Score: 0.017
  82. Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. J Clin Endocrinol Metab. 2012 Jan; 97(1):E110-4.
    View in: PubMed
    Score: 0.017
  83. Marine oil capsule therapy for the treatment of hyperlipidemia. Arch Intern Med. 1991 Sep; 151(9):1732-40.
    View in: PubMed
    Score: 0.016
  84. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011 Aug 15; 108(4):523-30.
    View in: PubMed
    Score: 0.016
  85. Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011 May; 161(5):972-8.
    View in: PubMed
    Score: 0.016
  86. Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. J Clin Lipidol. 2011 May-Jun; 5(3):141-151.
    View in: PubMed
    Score: 0.016
  87. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol. 2011 Mar 15; 107(6):906-11.
    View in: PubMed
    Score: 0.016
  88. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16; 363(25):2406-15.
    View in: PubMed
    Score: 0.016
  89. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol. 2010 May 15; 105(10):1409-12.
    View in: PubMed
    Score: 0.015
  90. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010; 10(2):73-84.
    View in: PubMed
    Score: 0.015
  91. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
    View in: PubMed
    Score: 0.015
  92. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009 Oct; 158(4):513-519.e3.
    View in: PubMed
    Score: 0.014
  93. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 01; 104(1):74-81.
    View in: PubMed
    Score: 0.014
  94. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA. 2009 Mar 18; 301(11):1131-9.
    View in: PubMed
    Score: 0.014
  95. Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. Clin Drug Investig. 2009; 29(4):215-29.
    View in: PubMed
    Score: 0.014
  96. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009 May; 204(1):208-15.
    View in: PubMed
    Score: 0.013
  97. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008 May 15; 101(10):1428-36.
    View in: PubMed
    Score: 0.013
  98. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
    View in: PubMed
    Score: 0.013
  99. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008; 28(10):625-34.
    View in: PubMed
    Score: 0.013
  100. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006 Dec 06; 296(21):2572-81.
    View in: PubMed
    Score: 0.012
  101. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol. 2006 Nov 07; 48(9):1782-90.
    View in: PubMed
    Score: 0.012
  102. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006 Oct; 22(10):2041-53.
    View in: PubMed
    Score: 0.012
  103. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006 Jul; 85(1-3):254-65.
    View in: PubMed
    Score: 0.011
  104. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006 Apr 15; 97(8):1198-205.
    View in: PubMed
    Score: 0.011
  105. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation. 2005 Jul 26; 112(4):563-71.
    View in: PubMed
    Score: 0.011
  106. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism. 2005 Jul; 54(7):939-46.
    View in: PubMed
    Score: 0.011
  107. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005 May; 162(5):947-53.
    View in: PubMed
    Score: 0.011
  108. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J. 2003 Nov; 146(5):862-9.
    View in: PubMed
    Score: 0.010
  109. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol. 2003 Mar 06; 91(5A):20C-23C; discussion 23C-24C.
    View in: PubMed
    Score: 0.009
  110. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol. 2003 Jan; 26(1):18-24.
    View in: PubMed
    Score: 0.009
  111. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord. 2003; 15(2):79-87.
    View in: PubMed
    Score: 0.009
  112. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002 Dec 03; 137(11):875-83.
    View in: PubMed
    Score: 0.009
  113. Consumption of diacylglycerol oil as part of a reduced-energy diet enhances loss of body weight and fat in comparison with consumption of a triacylglycerol control oil. Am J Clin Nutr. 2002 Dec; 76(6):1230-6.
    View in: PubMed
    Score: 0.009
  114. Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause. 2002 Jan-Feb; 9(1):16-22.
    View in: PubMed
    Score: 0.008
  115. Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. Am J Cardiol. 2001 Sep 15; 88(6):635-9.
    View in: PubMed
    Score: 0.008
  116. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis. 2001 Jul; 157(1):137-44.
    View in: PubMed
    Score: 0.008
  117. Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet. Am J Clin Nutr. 2001 Jul; 74(1):33-43.
    View in: PubMed
    Score: 0.008
  118. Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am Heart J. 2001 May; 141(5):722-6.
    View in: PubMed
    Score: 0.008
  119. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2001 05; 86(5):1890-7.
    View in: PubMed
    Score: 0.008
  120. Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. J Clin Pharmacol. 2001 Jan; 41(1):70-8.
    View in: PubMed
    Score: 0.008
  121. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001; 17(1):43-50.
    View in: PubMed
    Score: 0.008
  122. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism. 2000 Sep; 49(9):1234-8.
    View in: PubMed
    Score: 0.008
  123. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol. 2000 Aug 15; 86(4):406-11.
    View in: PubMed
    Score: 0.008
  124. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 2000 Jul 15; 86(2):221-3.
    View in: PubMed
    Score: 0.008
  125. Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. Am J Clin Nutr. 2000 Jun; 71(6):1433-8.
    View in: PubMed
    Score: 0.008
  126. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000 Feb; 85(2):720-6.
    View in: PubMed
    Score: 0.007
  127. Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol. 2000 Jan; 23(1):39-46.
    View in: PubMed
    Score: 0.007
  128. The efficacy of magnetic resonance imaging in acute knee injuries. Clin J Sport Med. 2000 Jan; 10(1):34-9.
    View in: PubMed
    Score: 0.007
  129. Cholesterol lowering with high-viscosity hydroxypropylmethylcellulose. Am J Cardiol. 1999 Nov 15; 84(10):1198-203.
    View in: PubMed
    Score: 0.007
  130. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin Pharmacol Ther. 1999 Jun; 65(6):653-60.
    View in: PubMed
    Score: 0.007
  131. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999 Jan 13; 281(2):137-44.
    View in: PubMed
    Score: 0.007
  132. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998 Dec; 18(12):1942-7.
    View in: PubMed
    Score: 0.007
  133. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998 Sep; 47(9):1097-104.
    View in: PubMed
    Score: 0.007
  134. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol. 1998 Aug 01; 82(3):311-6.
    View in: PubMed
    Score: 0.007
  135. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998 Feb; 27(2):267-74; discussion 274-5.
    View in: PubMed
    Score: 0.006
  136. Olestra's effect on vitamins D and E in humans can be offset by increasing dietary levels of these vitamins. J Nutr. 1997 08; 127(8 Suppl):1666S-1685S.
    View in: PubMed
    Score: 0.006
  137. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther. 1996 Sep-Oct; 18(5):853-63.
    View in: PubMed
    Score: 0.006
  138. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996 Jan 10; 275(2):128-33.
    View in: PubMed
    Score: 0.006
  139. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995 May; 15(5):678-82.
    View in: PubMed
    Score: 0.005
  140. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis. 1995 Jan 20; 112(2):223-35.
    View in: PubMed
    Score: 0.005
  141. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol. 1995 Jan 01; 75(1):34-9.
    View in: PubMed
    Score: 0.005
  142. Effects of ipsapirone in healthy subjects: a dose-response study. Psychopharmacology (Berl). 1994 Feb; 114(1):155-60.
    View in: PubMed
    Score: 0.005
  143. Venous leg ulceration: evaluation of zinc treatment, serum zinc and rate of healing. Clin Exp Dermatol. 1977 Dec; 2(4):395-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.